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Abstract—To determine whether cellular aging leads to a cardiomyopathy and heart failure, markers of cellular senescence,
cell death, telomerase activity, telomere integrity, and cell regeneration were measured in myocytes of aging wild-type
mice (WT). These parameters were similarly studied in insulin-like growth factor-1 (IGF-1) transgenic mice (TG)
because IGF-1 promotes cell growth and survival and may delay cellular aging. Importantly, the consequences of aging
on cardiac stem cell (CSC) growth and senescence were evaluated. Gene products implicated in growth arrest and
senescence, such as p27Kip1, p53, p16INK4a, and p19ARF, were detected in myocytes of young WT mice, and their
expression increased with age. IGF-1 attenuated the levels of these proteins at all ages. Telomerase activity decreased
in aging WT myocytes but increased in TG, paralleling the changes in Akt phosphorylation. Reduction in nuclear
phospho-Akt and telomerase resulted in telomere shortening and uncapping in WT myocytes. Senescence and death of
CSCs increased with age in WT impairing the growth and turnover of cells in the heart. DNA damage and myocyte death
exceeded cell formation in old WT, leading to a decreased number of myocytes and heart failure. This did not occur in
TG in which CSC-mediated myocyte regeneration compensated for the extent of cell death preventing ventricular
dysfunction. IGF-1 enhanced nuclear phospho-Akt and telomerase delaying cellular aging and death. The differential
response of TG mice to chronological age may result from preservation of functional CSCs undergoing myocyte
commitment. In conclusion, senescence of CSCs and myocytes conditions the development of an aging myopathy. (Circ
Res. 2004;94:514-524.)
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The accepted but never proven paradigm is that the heartis a postmitotic organ characterized by a predetermined
number of myocytes, which is defined shortly after birth and
is preserved throughout life till death of the organism.1
According to this view, age of cardiomyocytes corresponds to
the age of the organ and organism, ie, without exception,
cellular, organ, and organism age coincide. Myocytes must
age at the same pace and, at any given time, the heart should
be composed of a homogeneous population of myocytes of
identical age. Therefore, myocardial aging has been inter-
preted as a time-dependent biological process that interacts
with ischemic heart disease, hypertension, diabetes, and other
pathological conditions, which together define the clinical
phenotype.2 The possibility that cardiac aging is an indepen-
dent determinant of morbidity and mortality has faced oppo-
sition and emphasis has been placed on age-associated
changes, which increase the chances of cardiovascular events
in the elderly. Treatment of cardiac diseases in old patients
has resulted in a prolongation of average lifespan. However,
maximum lifespan has not increased in the last 70 years,3
suggesting that cellular aging may play a more important role
than generally expected.
Several lines of evidence have been obtained in favor of the
regeneration of the adult and aged myocardium4 through the
activation of cardiac stem cells (CSCs).5,6 A mitotic clock
regulates cellular lifespan that is not related to organ and
organism age and lifespan,7 raising the possibility that CSC
aging conditions myocyte aging and the development of an
aging myopathy. Although this may be seen as an oversim-
plification of a complex problem, myocardial aging may
result from senescence of myocytes due to attenuation in their
turnover dictated by CSC aging and the inevitable accumu-
lation of older cells. Therefore, the hypothesis being tested is
whether an imbalance between myocyte growth and death
induced by alterations in CSC function occurs with age
resulting in a decompensated myopathy. Conversely, growth
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factors enhancing cell replication and attenuating CSC and
myocyte senescence may delay the appearance of a cardio-
myopathic old heart.
Materials and Methods
An expanded Materials and Methods can be found in an online data
supplement available at http://circres.ahajournals.org.
Results
Myocyte Aging
Cellular aging is characterized by the expression of nuclear
proteins involved in cell cycle inhibition and irreversible
growth arrest. Growth factors promoting cell division may
interfere with cellular senescence.8 A most likely candidate is
insulin-like growth factor-1 (IGF-1) whose overexpression in
myocytes potentiates new myocyte formation in the adult
heart.9 Significant differences may exist in the phenotype of
aging myocytes in wild-type (WT) and IGF-1 transgenic
(TG) homozygous mice at 4, 10 to 12, and 20 to 22 months
of age. This likelihood would strengthen the notion that
senescence of parenchymal cells results in an aging myop-
athy, distinct from age-associated diseases.2
During aging, fibroblasts10 are arrested at G0-G1 by
transient expression of p21Cip1 followed by a temporary
upregulation of p27Kip1 and then by persistent elevation of
p16INK4a. A comparable role for p19ARF and p53 was recog-
nized in cellular aging.11 The regulation of p21Cip1 can be
p53-dependent or -independent12 and p19ARF increases p53
quantity and activity13 by decreasing Mdm2 expression.
A similar pattern of gene expression was found in vivo in
myocytes from aging WT: p21Cip1 decreased from 4 to 20 to
22 months, whereas p27Kip1, p16INK4a, and p19ARF increased.
The increase in p19ARF was coupled with an upregulation of
total and free p53 protein, which was paralleled by a decrease
in the formation of Mdm2-p53 inactive complexes (Figure 1).
IGF-1 opposed these age-dependent alterations in myocytes.
With respect to WT, p21Cip1 was detected in lower quantities
in TG myocytes at 4 and 10 to 12 months and was undetect-
able at 20 to 22 months. p27Kip1, p16INK4a, and p19ARF were
absent at 4 months and present in modest levels at 10 to 12
and 20 to 22 months. p53 increased moderately with age and
Mdm2-p53 complexes remained high in TG myocytes.
Myocyte Size, Oxidative Stress, p53, p16INK4a, and
Myocyte Death
In the aging failing heart, a subpopulation of myocytes
undergoes DNA replication and mitosis, another undergoes
hypertrophy, and another cell death.14 In animals and humans,
small myocytes are the only myocytes capable of replicating
DNA.5,14,15 There is an upper limit in myocyte volume,
90 000 m3, and cross-sectional area, 600 to 900 m2,
beyond which no further hypertrophy occurs.5,14 They are old
cells positive for p16INK4a and p53.15 The high proficiency of
these myocytes to die might be linked to accumulation of
oxidative products that exceeds cellular repair mechanisms.
The interdependence of oxidative damage and cell death is
well established in several systems including myocytes.15,16
However, the role of cell dimension and age in this process
remains to be determined.
Oxidative stress, identified by 8-hydroxy-2-
deoxyguanosine (8-OH-dG), varied from 200 to 1000 pixels
(pixelsfluorescence/fluorescence of propidium iodide per
nucleus) in apoptotic myocytes with cross-sectional area 400
to 600 m2. Higher signals were detected in apoptotic
myocytes with cross-sectional area 700 to 900 m2 (Figures
2A and 2B). With myocyte necrosis (Figures 2C and 2D), the
oxidative challenge was higher ranging from 600 to 5000
pixels. In both forms of death, the intensity of the 8-OH-dG
signal correlated directly with myocyte size, p16INK4a, p53,
and age (Figure 2E).
Figure 1. Inhibitors of myocyte replication and markers of cellu-
lar senescence. These proteins include p21Cip1, p27Kip1, p16INK4a,
p19ARF, and p53 (total, bound to p90 and p57-58 isoforms of
Mdm2, and free). Optical density (OD) is shown in online data
supplement.
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Myocyte apoptosis increased 4-fold from 4 (14960/106)
to 10 to 12 (622174/106) months and 12-fold from 4 to 20
to 22 (1804352/106) months (P0.001). Corresponding
increases in myocyte necrosis were 4-fold (31770/106
versus 1318352/106) and 30-fold (31770/106 versus
95102167/106) (P0.001). Cell necrosis was 2-fold, 2-fold,
and 5-fold greater than apoptosis at 4, 10 to 12, and 20 to 22
months, respectively (P0.001). Dying myocytes were
p16INK4a and p53 positive (Figures 2F and 2G), but not all
myocytes expressing these proteins were dying: p16INK4a-
positive myocytes were 256%, 4214%, and 8219%, and
p53-positive myocytes were 54%, 96%, and 158% in
WT mice at 4, 10 to 12, and 20 to 22 months, respectively.
IGF-1 decreased myocyte death. In comparison with WT,
myocyte apoptosis in TG was 11% (13233/106; NS), 68%
(19744/106), and 78% (39696/106; P0.001) lower at 4,
10 to 12, and 20 to 22 months, respectively. Decreases in
myocyte necrosis in TG were 7% (29650/106; NS), 71%
(37787/106), and 93% (666121/106; P0.001). Again,
cell death correlated directly with 8-OH-dG, cell size,
p16INK4a, p53, and age (Figures 2H and 2I). TG mice had
lower percentages of p16INK4a (95%, 157% and 3513%)
and p53 (31%, 52% and 94%) positive myocytes.
Telomere Dysfunction, Senescence, and Death
of Myocytes
Alterations in telomeres result in inhibition of cell replication,
myocyte senescence, and death.5,14,15 Telomeres are protected
by a complex of proteins including TRF1, TRF2, uncleaved
poly(ADP-ribose) polymerase (PARP) and DNA-dependent
protein kinase (DNA-PK). Telomere-binding proteins have
not been yet identified in myocytes; if present, a decrease in
their levels would indicate defects in telomere integrity17,18 of
noncycling myocytes. This could provide a link between
telomere shortening or uncapping and senescence and death
of these non-cycling myocytes. In fact, TRF2 decreased in
WT myocytes from 4 to 10 to 12 months becoming undetect-
able at 20 to 22 months. Cleaved PARP increased at 20 to 22
months, exceeding the uncleaved form. Telomere dysfunction
was aggravated by downregulation of the components of
DNA-PK with age: heterodimeric complex Ku86/Ku70 and
DNA-PK catalytic subunit. TRF1 was not influenced by
aging. The impact of aging on telomeric proteins was atten-
uated in TG myocytes (Figure 3).
Hypophosphorylated RB was predominant in aging WT
myocytes reflecting the upregulation of p16INK4a. IGF-1 pro-
duced an opposite effect; phosphorylated RB was several-
fold higher than hypophosphorylated RB and the phosphor-
ylated-to-hypophosphorylated RB ratio increased with age
(Figure 3). This condition may delay myocyte hypertrophy,
senescence, and death.
Telomere length is another parameter that regulates cell
division and survival in cycling cells17,18 and might regulate
survival of differentiated myocytes. Telomere length in myo-
cyte nuclei, cell cross section, and p16INK4a and p53 expres-
sion were plotted as a function of age. There was an inverse
relationship between myocyte size and telomere length in WT
and TG at 4 and 20 to 22 months of age; larger cells with
shorter telomeres were p16INK4a and p53 positive (Figures 4A
through 4E; online data supplement). IGF-1 interfered with
the age-dependent increases in myocyte size, telomeric short-
ening and p16INK4a and p53 proteins. In comparison with
young cells, telomere length decreased more in old WT than
in TG myocytes.
Figure 2. Oxidative stress and myocyte death. WT hearts at 10 to 12
and 20 to 22 months: A, Two nuclei [blue, propidium iodide (PI)] are
positive for 8-OH-dG (magenta dots; arrowheads) and one of the two
(B) is also labeled by hairpin 1 (white dots, arrowhead). Apoptotic
nucleus belongs to a large myocyte (red; -sarcomeric actin). C and
D, Myocyte necrosis: yellow dots (D, arrowhead) correspond to hairpin
2. E, Results are presented as scatter plots and as meanSD. * and †
Indicate statistical difference (P0.05) versus WT and animals at 4
months, respectively. F, Three nuclei express p16INK4a (green dots;
arrowheads) and two of the three (G) are labeled by hairpin 1 (white
dots, arrowheads). Apoptotic nuclei belong to large myocytes. H
and I, Myocyte necrosis: yellow dots (I, arrowheads) correspond to
hairpin 2.
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Telomerase Activity and Aging
Telomerase protects chromosomes from telomere erosion,
maintains cell replication, and opposes cell death.19,20 Telom-
erase competent myocytes are cycling and are p16INK4a and
p53 negative. Telomerase identifies young myocytes, actively
growing and replacing old dying myocytes.5,14,19 The
telomere-telomerase system is a cell-autonomous determinant
of organ aging. The catalytic subunit of telomerase was
higher in TG than WT myocytes (Figure 5A). Telomerase
activity in WT myocytes decreased from 4 to 20 to 22
months, but increased in TG myocytes. Moreover, enzyme
activity was higher in TG than in WT myocytes at each age
(Figures 5B through 5D).
IGF-1 activates the PI3K-Akt pathway, and this signaling
mechanism may phosphorylate and activate telomerase in TG
myocytes. We identified a consensus site for Akt phosphor-
ylation, RVRLRELSQE (amino acids 585 to 594), in the
mouse telomerase, suggesting that Akt potentiates telomerase
function.21 Thus, the amino acid sequence was labeled with
fluorescein and used in an Akt-kinase assay. Noninfected
myocytes and myocytes infected with an adenovirus carrying
a nuclear (Akt-nuc) or membrane (Akt-myr) targeted Akt or
Figure 3. Telomere-related proteins in myocytes. These proteins
include TRF-2, PARP, Ku86, Ku70, DNA-PKcs, TRF-1, and RB.
OD is shown in online data supplement.
Figure 4. Telomere length and colocalization of p16INK4a and p53
in myocytes. WT hearts at 4 and 20 to 22 months: A, Myocyte
(red; -sarcomeric actin) nuclei (blue, PI) with short telomeres
(magenta dots) show low levels of fluorescence (arrowheads). B,
Three of these nuclei express p16INK4a (green dots, arrows). A
similar finding is demonstrated in C and D. However, yellow
dots in D (arrows) correspond to p53. E, Distribution of myocyte
cross-sectional areas (CSA) and telomere lengths. Aging in WT
results in a shift in the distribution of CSA to the right and telo-
mere lengths to the left. The solid portion of the bars corre-
sponds to p16INK4a-positive myocyte nuclei; they increase with
age in both cases. In TG, these various changes are markedly
attenuated.
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dominant-negative form of Akt (Akt-DN) were used. Four
observations were made (Figures 5E and 5F): (1) At 20 to 22
months, noninfected TG myocytes had higher levels of
phosphorylated telomerase sequence than WT myocytes; (2)
Akt-nuc infection was involved in phosphorylation of telom-
erase sequence of WT myocytes; (3) Akt-DN decreased
substrate phosphorylation in TG myocytes; and (4) peptide
phosphorylation was proportional to Akt-nuc–infected WT
myocyte proteins.
Phosphorylation of telomerase by Akt was determined in
vivo to identify the role of Akt in telomerase function.
Telomerase protein was immunoprecipitated from freshly
isolated WT and TG myocytes and was then exposed to an
antibody against its phosphorylated Akt consensus site (Fig-
Figure 5. Telomerase and telomerase activity. A, Catalytic subunit of telomerase (TERT) in myocyte nuclear lysates. B through D, Prod-
ucts of telomerase activity start at 50 bp and display a 6-bp periodicity. Myocytes treated with RNase () were used as negative con-
trol and HeLa cells as positive control. Serial dilution of myocyte proteins (0.5 and 1.0 g) was used to confirm the specificity of the
reaction. E, Akt kinase assay of WT and TG myocyte nuclear lysates and nuclear lysates of WT and TG myocytes infected with empty,
Akt-myr, Akt-nuc, or Akt-DN vectors. Substrate utilized in the reaction corresponds to the sequence 585 to 594 of the mouse TERT.
Human TERT (hTERT) and histone 2B (H2B) were used as positive controls. F, Increasing amounts of proteins were used to confirm the
specificity of the reaction. G through J, Immunoblots of phospho-TERT, phospho-Akt, and total Akt in nuclear and whole-cell lysates. K
through M, Telomerase activity in myocytes infected with empty, Akt-myr, Akt-nuc, and Akt-DN vectors. OD is shown in online data
supplement.
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ure 5G). Phosphotelomerase level decreased in WT myo-
cytes, with age becoming barely detectable at 20 to 22
months. Conversely, phosphotelomerase increased progres-
sively as a function of age in TG myocytes. At all intervals,
phosphotelomerase was higher in TG than in WT myocytes,
paralleling the results of telomerase activity described earlier
(see Figures 5B through 5D).
The expression of Akt was measured in aging WT and TG
myocytes. Akt protein (total) remained constant and did not
differ in WT and TG myocytes. However, phospho-Akt
levels decreased in WT and increased in TG myocytes from
4 to 20 to 22 months (Figures 5H through 5J). These results
are consistent with attenuation and increase in telomerase
activity in aging WT and TG myocytes, respectively. To
confirm phospho-Akt function in the regulation of telomer-
ase, a TRAP assay was performed in old WT myocytes
infected with Akt-nuc or Akt-myr. Only Akt-nuc expression
resulted in a marked elevation in telomerase activity. Increas-
ing degrees of Akt-nuc infection of WT myocytes were
accompanied by increases in telomerase activity. Akt-myr
infection did not modify baseline telomerase in WT myo-
cytes. Telomerase activity in old TG myocytes was severely
depressed after infection with the Akt-DN adenovirus (Fig-
ures 5K through 5M).
Aging, Myocyte Growth, Number, and
Contractile Performance
Myocyte aging in WT mice typically shows alterations in
telomeres, telomerase activity, oxidative stress response, and
expression of p16INK4a and p53. These intrinsic determinants
of cellular senescence promote cell death and impair cell
growth, compromising cardiac structure and function. Myo-
cyte loss increases with age more than cell regeneration and
the excess in cell dropout leads to ventricular decompensa-
tion, suggesting that the aging myopathy is mediated by
molecular defects in myocytes. If this were the case, attenu-
ation of cell death and/or potentiation of cell growth should
preserve ventricular performance. These conditions are oper-
ative in IGF-1 TG mice.
For this purpose, the number of dying myocytes (hairpin 1
and hairpin 2) in the left ventricle was compared with the
number of forming cells (BrdU). In WT, the number of dying
myocytes was significantly higher than that of replicating
cells and this difference increased from 4 to 20 to 22 months.
Conversely, in TG, the values of cell death and cell prolifer-
ation were comparable at all ages. The rate of myocyte
formation was 3-fold higher in TG, and the rate of cell
death was4-fold higher in WT. Therefore, the total number
of ventricular myocytes decreased by 33% in WT at 20 to 22
months, whereas myocyte number remained constant in TG
mice (Figure 6). Myocyte loss in aging WT was associated
with elevation in LVEDP and a significant decrease in
LVDevP and  and  dP/dt (Figure 6). Ventricular
dysfunction was absent in TG mice; cell regeneration
maintained constant myocyte number in the old heart. The
cellular and functional indices of TG hearts at 20 to 22
months were comparable with those of WT hearts at 10 to
12 months.
At all ages, TG myocytes had higher peak shortening,
velocity of shortening, and relengthening than WT. Myo-
cyte contractility decreased with age in WT and remained
constant in TG, amplifying the difference between old WT
and TG. Developed Ca2 was higher in TG than WT
myocytes at high rate of stimulation. L-type Ca2 current
differed in amplitude being higher in young and old TG
than in WT, suggesting that TG myocytes have a more
efficient SR with enhanced reuptake and improved diastol-
ic relaxation. WT myocytes manifested a longer recovery
from inactivation than TG with age (Figures 7A and 7B;
online data supplement). Thus, the mechanical behavior of
myocytes contributed to the preservation of ventricular
hemodynamics in TG with age.
CSC Aging
Clusters of primitive and early committed cells expressing the
stem cell antigen c-kit were found in WT and TG myocardi-
Figure 5 (continued).
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um (Figure 8A). These cells were lineage negative (see
expanded Materials and Methods) or expressed the transcrip-
tion factors GATA-4 and MEF2C, which are implicated in
cardiac and myocyte differentiation, respectively.5,6,14 More-
over, -sarcomeric actin, cardiac myosin heavy chain, con-
nexin43, and N-cadherin were detected. New small myocytes
were telomerase competent and Ki67 positive (Figures 8B
and 8C), representing amplifying cells that divided rapidly
and differentiated.5,6,14 The recognition of cells positive for
c-kit, GATA-4, and cardiac myosin provided an indisputable
link between primitive cells, early differentiating myocytes,
and mature parenchymal cells (Figure 8D).
The number of c-kitPOS cells in the left ventricle was 47%
lower in WT than in TG at 4 months and this difference
increased to 56% at 20 to 22 months (Figure 8E). From 4 to
20 to 22 months, there was an increase of 1.9- and 2.3-fold in
the number of c-kitPOS cells in WT and TG, respectively.
However, the expression of p16INK4a was detected in 70% of
WT c-kitPOS cells, indicating a block in their ability to reenter
the cell cycle and divide. This phenomenon involved only
16% of TG c-kitPOS cells (Figure 8F). Importantly, apoptosis
was 3-fold and 5-fold higher in WT than in TG c-kitPOS cells
at 4 and 20 to 22 months, respectively. These results on cell
death amplified the difference in the pool size of functionally
competent CSCs between WT and TG. As in myocytes, all
apoptotic c-kitPOS cells expressed p16INK4a (Figures 8G and 8H).
To estimate the length of telomeres in c-kitPOS cells, a Q-FISH
with a probe complementary to the telomere sequence was
performed. Nuclei with short telomeres expressed p16INK4a in
both WT and TG c-kitPOS cells. The combination of short
telomeres and p16INK4a was more prominent in WT than in TG
c-kitPOS cells at 4 and 20 to 22 months. Additionally, the largest
fraction of c-kitPOS cells labeled by p16INK4a was detected in old
WT that had the shortest telomeres (Figure 8I).
Discussion
Decompensated Aging Heart
The objective of this study was to establish whether aging of
the heart leads to molecular modifications of myocytes that
profoundly alter the characteristics and performance of the
old heart resulting in a failing myopathy. These cellular
age-dependent effects are dictated by senescence of CSCs,
which become largely unable to divide and generate new
functionally competent myocytes. CSC apoptosis further
attenuates the growth reserve of the myocardium as well as its
ability to replace dying myocytes and respond adequately to
the increases in physiological loads imposed by myocyte
dropout. Myocytes lose with time their youth; the myocyte
compartment becomes progressively less heterogeneous with
large cells comprising the majority of the myocardium. The
normal spectrum of developing, maturing, and senescent
myocytes, typical of the adult and middle-aged heart, is no
longer apparent and hypertrophied myocytes predominate.
Cardiac aging may be viewed as a limitation in the
replication and commitment of CSCs that affects the turnover
of myocytes favoring cell loss and the accumulation of old
poorly contracting cells. These cells cannot be adequately
replaced by new amplifying myocytes undergoing cell divi-
sion and maturation5,14 in order to meet the functional needs
of the aged heart.2,22 A similar phenomenon is operative in
other organs.11,18 Cell death coupled with an increased num-
ber of myocytes with depressed contractile behavior underlies
the onset of cardiac decompensation. The results in WT are
consistent with observations in rats4 and in large animals,23
although not all studies are in agreement.24 Heart failure in
individuals 66 years of age and older, up to 103 years, has no
other confounding variables in nearly 50% of the cases,
suggesting that age may be a primary cause of cardiac
decompensation and diastolic dysfunction.25
In TG mice, CSCs are more numerous and actively
growing enhancing myocyte turnover, preserving myocyte
number, attenuating the accumulation of hypertrophied myo-
cytes, and increasing the number of new functionally efficient
young cells. Together, these factors maintain ventricular
function and prevent heart failure, strengthening the conten-
tion that cardiac aging occurs at the cellular level. These
findings are at variance with the view that IGF-1 promotes
premature aging in fruit flies, nematodes, and mice26 but are
consistent with the notion that IGF-1 delays aging and heart
failure in humans.27 However, it is difficult to discriminate
Figure 6. Myocyte volume and number and left ventricular (LV)
function. Results are meanSD. Symbols indicate statistical dif-
ference (P0.05) versus animals at 4* and 10 to 12** months
and WT† mice. LVEDP indicates LV end-diastolic pressure;
LVDevP, LV developed pressure.
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whether changes in CSCs are primary or secondary events of
the aging cardiomyopathy.
Myocyte Senescence
Cellular senescence is characterized by biochemical events
that occur within the cell leading to growth arrest and loss of
specialized cellular functions.11,18 These defects, such as
repeated oxidative stress, may evolve into the activation of
cell death or result in the development of a senescent
phenotype. The old cells in the heart do not differ from those
in other organs.28 Senescent cells cannot divide, their ability
to synthesize proteins or secrete autacoids and hormones is
reduced, and the antioxidant defense mechanisms and the
DNA repair system are attenuated.29 In myocytes, in which
cell replication is already lost, aging leads to a block in the
capacity to hypertrophy.5,13 Myocyte mechanics and Ca2
transients are altered indicating that the systems regulating
activation, contraction and relaxation are defective. A pres-
ervation of myocyte mechanical behavior coupled with a
reduced response to norepinephrine has been seen in aging
Wistar rats.30,31 Importantly, there is an upper limit to
myocyte growth; cells with cross-sectional areas 300 to 500
m2 do not replicate but can hypertrophy, whereas myocytes
600 to 900 m2 do not incorporate BrdU, do not hypertrophy
and express p16INK4a and/or p53.5,14,15
p53 modulates apoptosis and senescence by increasing the
expression of specific proteins, including Bax, Bad, and
p21Cip1. Bax and Bad are implicated in apoptosis, whereas
high levels of p21Cip1 are involved in irreversible growth
arrest and cellular senescence.18 Low quantities of p21Cip1,
however, result in transient inhibition of cell growth. p16INK4a
blocks the cell cycle by maintaining RB in its hypophosphor-
ylated state; RB interferes with the cell cycle by repressing
the E2F transcription factors. Therefore, p16 INK4a is an ideal
inducer of cellular senescence. The p16INK4a/RB pathway
promotes also apoptosis by increasing p53 through Mdm2
downregulation.13,32 Why a cell undergoes apoptosis or se-
nescence in response to identical stimuli is unclear. However,
apoptosis and senescence are influenced by the intensity and
duration of the inciting stimulus, the past history of the cell,
and environmental cues.18 IGF-1 in myocytes counteracts
these variables, limiting the expression of age-related genes
and cell death inducers.
Myocytes, Telomeres, and Telomerase
Chromosomal ends contain long stretches of hexameric
sequences, the telomeres, which bind specific proteins. Te-
lomerase and telomere-binding proteins maintain telomere
integrity and cell viability.15,19,20 The presence of short or
uncapped telomeres discriminates old from young cells and
conditions cell fate.19 In WT, enlarged cells with shortened
and uncapped telomeres characterize myocyte senescence.
Telomere attrition initiating the senescence program or cell
death is identical in young and old myocytes but the number
of cells involved differs in magnitude. Senescent WT myo-
Figure 7. Contractile activity in myocytes. A and B, Representative tracings illustrating peak shortening and velocity of shortening and
relengthening, Ca2 transients, and L-type Ca2 current. Results are meanSD. * and † Indicate statistical difference (P0.05) versus
animals at 10 to 12 months and WT mice, respectively.
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cytes have telomeres of 15 kbp instead of 30 kbp, express
p16INK4a, p53, and show modest levels of 8-OH-dG in the
nucleus. However, cell death is coupled with high levels of
8-OH-dG. IGF-1 overexpression does not change the prop-
erties of senescent and dying myocytes in terms of telomere
length and expression of p16INK4a and p53. IGF-1 reduces
myocyte senescence and death; telomerase activity is en-
hanced in younger myocytes and this enzyme protects from
telomeric shortening, oxidative injury, growth arrest, and cell
death. The expression of proteins implicated in DNA repair
and telomere integrity, Ku86/Ku70, PARP, and TRF2, de-
creases with age in WT but remains constant in TG, pointing
to an antiaging effect of IGF-1. Telomere erosion at each
round of cell division, oxidative stress, and downregulation of
telomeric proteins define myocyte senescence.
Cardiac Stem Cells
The process of CSC senescence follows a pattern similar to
that identified in this study in myocytes of rodents and
previously in humans.14 This process is characterized by the
expression of p16INK4a and telomeric shortening. Because of
this CDK inhibitor, a large number of c-kitPOS cells cannot
divide symmetrically or asymmetrically and maintain the
CSC pool. The increase in c-kitPOS cells undergoing senes-
Figure 8. Cardiac stem cells. WT heart at 4 months: A, cluster of c-kit–positive cells (green, arrowheads). Five of these cells express
GATA-4 (white dots, arrows) in nuclei (blue, PI). Myocytes (red; -sarcomeric actin). B and C illustrate the same field. Magenta fluores-
cence dots in B correspond to telomerase (arrowheads) in two myocyte nuclei. Green dots in C depict Ki67 labeling in the same two
nuclei (arrowheads). D, One c-kit–positive cell (green, arrowhead) expresses MEF2C (yellow) in the nucleus and -sarcomeric actin in
the cytoplasm (red). E and F, Results are meanSD. * and † Indicate statistical difference (P0.05) versus animals at 4 months and WT
mice, respectively. G and H illustrate the same field in a WT heart at 20 to 22 months. Two c-kit–positive cells (green) express p16INK4a
(yellow dots, arrowheads) in their nuclei (blue, PI). One c-kit-p16INK4a–positive cell is labeled by hairpin 1 (white dots, arrow). I, Distribu-
tion of telomere length in CSCs. Aging in WT results in a shift to the left in the distribution of telomere lengths. Solid bars correspond
to p16INK4a-positive CSC nuclei; they increase with age. In TG, these changes are markedly attenuated.
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cence and death interferes with the needs for myocyte
replacement in the old heart. This deficiency promotes
differentiation of the remaining p16INK4a-negative c-kitPOS
cells into amplifying myocytes. The higher fraction of CSCs
undergoing myocyte commitment is consistent with the
increase in BrdU labeling of WT myocytes with age. CSC
senescence, on the one hand, and differentiation, on the other,
leads to a progressive depletion of the growth reserve of the
heart. Although transgene expression was myocyte restricted,
overexpression of the secreted form of IGF-1 had an impact
on CSC function. IGF-1 accumulates at high concentration in
myocytes where it is then secreted in the interstitium.9 The
released IGF-1 binds to IGF-1 receptors present on CSCs
(unpublished data, 2004). The IGF-1/IGF-1 receptor system
induces CSC division, enhances telomerase activity, delays
senescence, and preserves the reservoir of functionally com-
petent CSCs (unpublished data, 2004). But whether IGF-1–
mediated attenuation of p53, angiotensin II formation, oxida-
tive stress, and myocyte death14,16,32 is operative in CSCs
remains to be determined. Importantly, IGF-1 suppresses the
ASK-1–induced activation of JNK/p38 kinase and apopto-
sis.33 In fact, the expression of IGF-1 increases in the
surviving myocytes after infarction and this response
prevents the activation of myocyte apoptosis in the over-
loaded spared myocardium positively interfering with
side-side slippage, ventricular dilation, and wall thinning
of the postinfarcted heart.34,35 Thus, CSCs and IGF-1
protect myocardial regeneration and delay organ aging and
heart dysfunction.
Akt and Myocardial Aging
On the basis of this discussion, cardiac aging is a time-
dependent process that consistently attenuates myocyte turn-
over mediated by growth limitation at the level of the
controlling cell, the CSC. In the old heart, the myocyte
commitment of CSCs is severely reduced by senescence and
death of this cell compartment and the postulated decrease in
the number of rounds of division of amplifying myocytes.
Telomerase activity is markedly decreased in amplifying
myocytes leading to premature telomeric shortening and
growth arrest. The principal defect seems to be linked to
diminished nuclear expression of phospho-Akt. This kinase
has the ability to promote phosphorylation of telomerase
enhancing enzyme activity and, thereby, cell growth and
survival delaying the onset of the aging myopathy. The
PI3K-Akt signaling pathway is partially rescued by IGF-1
overexpression that upregulates nuclear phospho-Akt func-
tion and telomerase.
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